Table 2. Comparison of Selected Susceptibility Profiles of Gram-Negative Bacilli Causing Healthcare-associated Infections among Case and Control Subjects.
| Antimicrobial Agent | Case Subjects (n=103) | Control Subjects (n=195) |
|---|---|---|
| Susceptible n/Na (%) | Susceptible n/Na (%) | |
| Amikacin | 15/96 (15) | 193/195 (99) |
| Cefepime | 7/98 (7) | 166/193 (86) |
| Ciprofloxacin | 0/50 (0) | 86/96 (90) |
| Gentamicin | 16/102 (16) | 178/196 (91) |
| Imipenem | 1/67 (1) | 129/142 (91) |
| Levofloxacin | 0/102 (0) | 167/195 (86) |
| Meropenem | 6/82 (7) | 127/140 (91) |
| Piperacillin-tazobactam | 1/51 (2) | 76/87 (87) |
| Polymyxin Bb | 75/83 (90) | 14/14 (100) |
| Tigecyclinec | 58/85 (68) | 5/9 (56) |
| Trimethoprim-sulfamethoxazole | 1/101 (1) | 100/121 (83) |
| Tobramycin | 3/82 (4) | 162/170 (95) |
a
n= number susceptible isolates and N= number of isolates with available results
b
Interpretive criteria do not exist for the Enterobacteriacae when testing polymyxin B; therefore, the susceptible breakpoint of ≤2 μg/mL approved for P. aeruginosa and Acinetobacter spp. was employed for these organisms.
c
Interpretive criteria do not exist for the Acinetobacter spp. when testing tigecycline; therefore, the susceptible breakpoint of ≤2 μg/mL approved for Enterobacteriacae was employed for these organisms.